| pubmed-article:11006042 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11006042 | lifeskim:mentions | umls-concept:C1140680 | lld:lifeskim |
| pubmed-article:11006042 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:11006042 | lifeskim:mentions | umls-concept:C0146224 | lld:lifeskim |
| pubmed-article:11006042 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:11006042 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:11006042 | lifeskim:mentions | umls-concept:C0086960 | lld:lifeskim |
| pubmed-article:11006042 | lifeskim:mentions | umls-concept:C1521801 | lld:lifeskim |
| pubmed-article:11006042 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:11006042 | pubmed:dateCreated | 2000-10-16 | lld:pubmed |
| pubmed-article:11006042 | pubmed:abstractText | PURPOSE; The aim of this study was to investigate the toxicity and efficacy of a more convenient topotecan administration schedule (in contrast to the "standard" 1.5 mg/m(2)/day x 5 days q 21 days) in the management of platinum- and paclitaxel-refractory ovarian cancer. | lld:pubmed |
| pubmed-article:11006042 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11006042 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11006042 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11006042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11006042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11006042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11006042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11006042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11006042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11006042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11006042 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11006042 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:11006042 | pubmed:issn | 0090-8258 | lld:pubmed |
| pubmed-article:11006042 | pubmed:author | pubmed-author:KennedyAA | lld:pubmed |
| pubmed-article:11006042 | pubmed:author | pubmed-author:PetersonGG | lld:pubmed |
| pubmed-article:11006042 | pubmed:author | pubmed-author:BelinsonJJ | lld:pubmed |
| pubmed-article:11006042 | pubmed:author | pubmed-author:WebsterKK | lld:pubmed |
| pubmed-article:11006042 | pubmed:author | pubmed-author:MarkmanMM | lld:pubmed |
| pubmed-article:11006042 | pubmed:author | pubmed-author:KuloAA | lld:pubmed |
| pubmed-article:11006042 | pubmed:copyrightInfo | Copyright 2000 Academic Press. | lld:pubmed |
| pubmed-article:11006042 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11006042 | pubmed:volume | 79 | lld:pubmed |
| pubmed-article:11006042 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11006042 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11006042 | pubmed:pagination | 116-9 | lld:pubmed |
| pubmed-article:11006042 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:11006042 | pubmed:meshHeading | pubmed-meshheading:11006042... | lld:pubmed |
| pubmed-article:11006042 | pubmed:meshHeading | pubmed-meshheading:11006042... | lld:pubmed |
| pubmed-article:11006042 | pubmed:meshHeading | pubmed-meshheading:11006042... | lld:pubmed |
| pubmed-article:11006042 | pubmed:meshHeading | pubmed-meshheading:11006042... | lld:pubmed |
| pubmed-article:11006042 | pubmed:meshHeading | pubmed-meshheading:11006042... | lld:pubmed |
| pubmed-article:11006042 | pubmed:meshHeading | pubmed-meshheading:11006042... | lld:pubmed |
| pubmed-article:11006042 | pubmed:meshHeading | pubmed-meshheading:11006042... | lld:pubmed |
| pubmed-article:11006042 | pubmed:meshHeading | pubmed-meshheading:11006042... | lld:pubmed |
| pubmed-article:11006042 | pubmed:meshHeading | pubmed-meshheading:11006042... | lld:pubmed |
| pubmed-article:11006042 | pubmed:meshHeading | pubmed-meshheading:11006042... | lld:pubmed |
| pubmed-article:11006042 | pubmed:meshHeading | pubmed-meshheading:11006042... | lld:pubmed |
| pubmed-article:11006042 | pubmed:meshHeading | pubmed-meshheading:11006042... | lld:pubmed |
| pubmed-article:11006042 | pubmed:meshHeading | pubmed-meshheading:11006042... | lld:pubmed |
| pubmed-article:11006042 | pubmed:meshHeading | pubmed-meshheading:11006042... | lld:pubmed |
| pubmed-article:11006042 | pubmed:meshHeading | pubmed-meshheading:11006042... | lld:pubmed |
| pubmed-article:11006042 | pubmed:meshHeading | pubmed-meshheading:11006042... | lld:pubmed |
| pubmed-article:11006042 | pubmed:meshHeading | pubmed-meshheading:11006042... | lld:pubmed |
| pubmed-article:11006042 | pubmed:meshHeading | pubmed-meshheading:11006042... | lld:pubmed |
| pubmed-article:11006042 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:11006042 | pubmed:articleTitle | Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. | lld:pubmed |
| pubmed-article:11006042 | pubmed:affiliation | Gynecologic Cancer Program, The Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA. | lld:pubmed |
| pubmed-article:11006042 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11006042 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11006042 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11006042 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11006042 | lld:pubmed |
